Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Atherosclerosis
Related studies linked through entity extraction aliases.
Counseling Hepatitis C Virus (HCV) Positive Patients for Cardiovascular Disease Risk Factors
- Status
- COMPLETED
- Phase
- NA
Periodontal Disease, Inflammation and Acute Coronary Syndromes
- Status
- COMPLETED
- Phase
- N/A
Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination
- Status
- COMPLETED
- Phase
- NA
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
- Status
- COMPLETED
- Phase
- N/A
Interstitial Fluid in the Development of Cardiovascular Disease
- Status
- COMPLETED
- Phase
- N/A
Intravascular Imaging- Versus Angiography-Guided Percutaneous Coronary Intervention For Complex Coronary Artery Disease
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease
- Status
- UNKNOWN
- Phase
- NA
The Effect of Statin Treatment on Trained Innate Immunity
- Status
- COMPLETED
- Phase
- N/A
Prolonged Sitting on Responses to Short-Term Exercise Training
- Status
- COMPLETED
- Phase
- NA
IMaging Della PLAcca Carotidea
- Status
- COMPLETED
- Phase
- PHASE3
Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment
- Status
- COMPLETED
- Phase
- PHASE2
Sonodynamic Therapy on Patients With Femoropopliteal PAD and Claudication
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Beta-glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT)
- Status
- UNKNOWN
- Phase
- NA
Disease Prevention in Clinical Practice Base on Patient Specific Physiology
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
18F-Flutemetamol and Plaque Vulnerability
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
- Status
- TERMINATED
- Phase
- PHASE4
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
- Status
- COMPLETED
- Phase
- NA
18F-fluorocholine PET-MR Imaging of Coronary Plaque Vulnerability
- Status
- COMPLETED
- Phase
- N/A